Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 76(2020), 5 vom: 24. Mai, Seite 735-737 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vieira, Carolina Pinto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
030Y90569U |
|---|
| Anmerkungen: |
Date Completed 07.10.2020 Date Revised 07.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00228-020-02837-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305794949 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305794949 | ||
| 003 | DE-627 | ||
| 005 | 20231225121943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-020-02837-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1019.xml |
| 035 | |a (DE-627)NLM305794949 | ||
| 035 | |a (NLM)31982921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vieira, Carolina Pinto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2020 | ||
| 500 | |a Date Revised 07.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Chagas disease | |
| 650 | 4 | |a Elderly patients | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Nebivolol | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 7 | |a Glucuronides |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Nebivolol |2 NLM | |
| 650 | 7 | |a 030Y90569U |2 NLM | |
| 700 | 1 | |a Neves, Daniel Valente |e verfasserin |4 aut | |
| 700 | 1 | |a Nardotto, Glauco Henrique Balthazar |e verfasserin |4 aut | |
| 700 | 1 | |a Cesarino, Evandro José |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Zanardi, Ailton Marcelo Castilho Teno |e verfasserin |4 aut | |
| 700 | 1 | |a Lanchote, Vera Lucia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d 1971 |g 76(2020), 5 vom: 24. Mai, Seite 735-737 |w (DE-627)NLM000099538 |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:5 |g day:24 |g month:05 |g pages:735-737 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00228-020-02837-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 5 |b 24 |c 05 |h 735-737 | ||